Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2021 16:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and SEATTLE, April 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and...
March 30, 2021 16:26 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

Key presentations for BION-1301 at the ISN World Congress of Nephrology 2021 in April include Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of...
March 16, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy

Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021 VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE...
March 02, 2021 16:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
March 01, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient...
February 23, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit

Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials ...
February 17, 2021 16:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
February 02, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria

CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021 VANCOUVER, British Columbia and SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:...
January 04, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and SEATTLE, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
December 08, 2020 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

VANCOUVER, British Columbia and SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right